



Nexstim Receives NBS 5+ System Order from Pediatric Hospital in United States

Press release, Helsinki, 23 September 2025 at 9:15 AM (EEST)

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5+ from a new pediatric hospital customer in Midwestern United States.

The NBS (Navigated Brain Stimulation) System 5 is the only FDA-cleared and CE-marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. The system is mainly used for neurosurgical diagnostics: one of the most crucial pieces of information needed for neurosurgery or radiotherapy is the tumor's or other lesion's location in relation to the essential functions and their connections in the patient's brain. nTMS mapping with Nexstim's NBS system can give this information regarding motor and speech areas — it can be invaluable when deciding the best treatment option. The NBS 5+ system includes a therapy module that is FDA-cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States.

Mikko Karvinen, CEO of Nexstim, comments: *"We have been pleased to gain multiple renowned children's hospitals as our customers this year. Our systems enable a child-friendly environment for conducting motor and speech mapping, and we are honored to be involved in offering any help for families facing difficult situations."*

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO

+358 50 326 4101

mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim's Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.

Nexstim's Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com